Sign in

CRIS on Nasdaq

CURIS INC

In its 2026 annual report the company says: “We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3.”5 It is headquartered in Lexington, United States.2 Its shares trade on Nasdaq under the symbol CRIS.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Taysha Gene Therapies, Inc., Alpha Cognition Inc. or TScan Therapeutics, Inc., or pick any stock.

  • TickerCRIS on Nasdaq2
  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersLexington, United States2
  • Incorporated inDE3
  • Business address128 Spring Street, Building C, Suite 500, Lexington, Ma 024213
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5299000YO6CX4WMFVX062
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 31520502

See how the biggest companies compare on our leaderboards

We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, or PCNSL, in combination with ibrutinib, a Bruton Tyrosine Kinase inhibitor or BTK inhibitor and in our recently initiated TakeAim CLL study, a Phase 2 combination study of emavusertib in chronic lymphocytic leukemia, or CLL, with zanubrutinib, a BTK inhibitor. Our monotherapy and combination studies of emavusertib in AML are substantially complete. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration, or FDA, for the treatment of PCNSL, AML and MDS and from t…5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-60.5%Operating margin6
-80.3%Net margin6
-13.4%Revenue growth, 20256
-138.8%Return on equity6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Other costs100¢$9.4M

Out of $9.4M in revenue.6 The company lost money this year.

Financial statements

Revenue789106$9.4M in 2025−6% since 2019
0$5.0M$10.0M$15.0M2019: $10.0M$10.0M20192020: $10.8M$10.8M2020+8%2021: $10.6M$10.6M2021−2%2022: $10.2M$10.2M2022−5%2023: $10.0M$10.0M2023−1%2024: $10.9M$10.9M2024+9%2025: $9.4M$9.4M2025−13%
Operating income789106-$5.7M in 2025−77% since 2019
-$60.0M-$40.0M-$20.0M02019: -$24.4M-$24.4M20192020: -$24.9M-$24.9M2020+2%2021: -$42.1M-$42.1M2021+69%2022: -$53.0M-$53.0M2022+26%2023: -$48.3M-$48.3M2023−9%2024: -$44.5M-$44.5M2024−8%2025: -$5.7M-$5.7M2025−87%
Net income789106-$7.6M in 2025−76% since 2019
-$60.0M-$40.0M-$20.0M02019: -$32.1M-$32.1M20192020: -$29.9M-$29.9M2020−7%2021: -$45.4M-$45.4M2021+52%2022: -$56.7M-$56.7M2022+25%2023: -$47.4M-$47.4M2023−16%2024: -$43.4M-$43.4M2024−8%2025: -$7.6M-$7.6M2025−83%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Revenues, net$9.4M$10.9M
Cost of royalties$45.0K$98.0K
Research and development$28.3M$38.6M
General and administrative$14.0M$16.8M
Total operating expenses$42.3M$55.5M
Gain on release of liability related to sale of future royalties associated with sale of assets$27.2M$0
Loss from operations-$5.7M-$44.5M
Interest income$316.0K$1.8M
Expense related to the sale of future royalties-$2.2M-$615.0K
Total other income (expense)-$1.9M$1.2M
Net loss per common share, basic (in dollars per share)-$0.58-$6.88
Net loss per common share, diluted (in dollars per share)-$0.58-$6.88
Weighted average common shares, basic (in shares)13.2M shares6.3M shares
Weighted average common shares, diluted (in shares)13.2M shares6.3M shares
Net loss-$7.6M-$43.4M
Unrealized gain (loss) on marketable securities$0-$229.0K
Comprehensive loss-$7.6M-$43.6M

Compare CURIS INC with another company

Corporate structure

CURIS INC sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CURIS INC

  • CURIS INC Lexington, Massachusetts, United States
    • Curis Securities Corporation Subsidiary · Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CURIS INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$913.0K6 Dec 31, 2025$1.2M6 Dec 31, 2024−26.6%
Accumulated depreciation$851.0K6 Dec 31, 2025$1.0M6 Dec 31, 2024−16.0%
Property and equipment, net$62.0K6 Dec 31, 2025$231.0K6 Dec 31, 2024−73.2%
Operating-lease assets (leased space)$1.9M6 Dec 31, 2025$3.2M6 Dec 31, 2024−40.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$5.1M6 Dec 31, 2025$20.0M6 Dec 31, 2024−74.7%
Marketable securities, current$010 Dec 31, 2024$29.7M10 Dec 31, 2023−100.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$9.0M6 Dec 31, 2025$9.0M6 Dec 31, 20240%

Properties, in its own words

Our headquarters consist of office and laboratory space in Lexington, Massachusetts. We occupy approximately 21,772 feet of space under a lease agreement, which we entered into in December 2019 and which was amended in January 2022. We believe this office and laboratory space will be sufficient to meet our needs for the foreseeable future and that suitable additional space will be available as and when needed.

Item 2 of the 10-K filed Mar 24, 2026.5

Leadership

Who has led CURIS INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Daniel R. Passeri2006–2014
  2. Ali Ph.d. Fattaey2014–2018
  3. James E. Dentzer2018–now

President

  1. Mark Noel2008–2010
  2. Mitchell Keegan2009–2011
  3. Ali Ph.d. Fattaey2013–2018
  4. David Tuck2016
  5. James E. Dentzer2018–now

Chief financial officer

  1. James E. Dentzer2016–2018
  2. William Steinkrauss2019–2022
  3. Diantha Duvall2022–now

Chief operating officer

  1. Ali Ph.d. Fattaey2013–2014
  2. James E. Dentzer2018
2010201520202025
Board members and other officers (26)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Curis Securities Corporation Massachusetts4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Jul 30, 20268-K Listing notice or transfer49
  2. Jul 2, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed50
  3. Jul 1, 20268-K Bylaws or fiscal year changed51
  4. Jul 1, 20268-K Bylaws or fiscal year changed52
  5. Jun 25, 20268-K Shareholder vote53
  6. May 22, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Shareholder vote54
  7. May 12, 20268-K Results of operations55
  8. May 1, 20268-K Listing notice or transfer56
  9. Mar 19, 20268-K Results of operations57
  10. Mar 17, 20268-K Change to shareholders' rights; Executive or director change; Bylaws or fiscal year changed58
  11. Feb 9, 20268-K Listing notice or transfer59
  12. Jan 8, 20268-K Entered a material agreement; Unregistered sale of shares; Bylaws or fiscal year changed60
  13. Sep 27, 2018New chief executive James E. Dentzer becomes CEO15
  14. Jun 3, 2014New chief executive Ali Ph.d. Fattaey becomes CEO16
  15. Jun 2, 2006New chief executive Daniel R. Passeri becomes CEO17

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($9.80) a share, on Nov 6, 2025.61

When it reported results

  1. May 12, 2026Reported quarterly or annual results55
  2. Mar 19, 2026Reported quarterly or annual results57
  3. Nov 6, 2025Reported quarterly or annual results62
  4. Aug 5, 2025Reported quarterly or annual results63
  5. May 6, 2025Reported quarterly or annual results64
  6. Mar 31, 2025Reported quarterly or annual results65
  7. Mar 28, 2025Reported quarterly or annual results66
  8. Nov 14, 2024Reported quarterly or annual results67

Drug trials and FDA: coming up

  1. Jul 2027Phase 1/2 trial readout expected Phase 1/2 trial of Emavusertib and Ibrutinib in Relapsed Hematologic Malignancy: primary completion expected Jul 2027 (ClinicalTrials.gov NCT03328078).68

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

245 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 60 major events, 68 insider forms, 31 large holders, 65 other. The latest 20:

  1. Aug 14, 202610-Q EDGAR
  2. Aug 13, 2026424B4 EDGAR
  3. Aug 12, 2026EFFECT EDGAR
  4. Aug 10, 2026S-1 EDGAR
  5. Jul 30, 20268-K EDGAR
  6. Jul 17, 2026DRS EDGAR
  7. Jul 9, 20264 EDGAR
  8. Jul 9, 20264 EDGAR
  9. Jul 9, 20264 EDGAR
  10. Jul 9, 20264 EDGAR
  11. Jul 9, 20264 EDGAR
  12. Jul 9, 20264 EDGAR
  13. Jul 9, 20264 EDGAR
  14. Jul 9, 20264 EDGAR
  15. Jul 2, 20268-K EDGAR
  16. Jul 1, 20268-K/A EDGAR
  17. Jul 1, 20268-K EDGAR
  18. Jun 25, 20268-K EDGAR
  19. Jun 5, 2026DEF 14A EDGAR
  20. May 22, 2026PRE 14A EDGAR

The 245 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 1 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 31, 2026KAITIN KENNETH IDirectorBuy10,000$0.55$5.5KForm 4
Jan 31, 2022Dentzer James EPresident & CEOSale3,094$3.07$9.5KForm 4
Jan 27, 2022Dentzer James EPresident & CEOSale2,406$3.18$7.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
SBI Securities Co., Ltd.15$80.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How CURIS INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCURIS INC1
  • CIK0001108205
  • Employer ID (EIN)04-35051165
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address128 Spring Street, Building C, Suite 500, Lexington, MA 024211
  • Phone617-503-65001
  • Shares outstanding2,090,077 as of Aug 11, 202612
  • Public float$24.8M as of Jun 30, 20255
  • AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts PCAOB ID 238; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceMar 6, 20001
  • Filings1,208 in all: 4 (429), 8-K (253), 10-Q (79), SC 13G/A (63), SC 13G (31), DEF 14A (29), 10-K (25), 3 (25)1
    All 49 form types

    S-8 (22), CORRESP (21), UPLOAD (20), CT ORDER (18), DEFA14A (18), 424B5 (17), ARS (15), EFFECT (15), S-3 (15), 4/A (12), PRE 14A (11), SCHEDULE 13G/A (11), 425 (10), 8-K/A (8), 5 (7), S-4/A (6), 10-Q/A (5), SCHEDULE 13G (5), 10-K/A (3), 424B3 (3), FWP (3), REGDEX (3), S-1 (3), SC 13D/A (3), 3/A (2), POS AM (2), SC 13D (2), 10-K405 (1), 424B2 (1), 424B4 (1), 8-A12G (1), D (1), DRS (1), NT 10-K (1), NT 10-Q (1), POSASR (1), S-1/A (1), S-3/A (1), S-3ASR (1), S-3MEF (1), S-4 (1)

  • Latest filingsAnnual report (10-K) Mar 24, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Jun 5, 2026
    Latest 8-K (8-K) Jul 30, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.01 par value per shareCRISNasdaq

From the cover page of the 10-K filed Mar 24, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks CURIS INC names in Item 1A of its 10-K filed Mar 24, 2026: 61 risks under these headings, as written.5

  • RISKS RELATING TO OUR FINANCIAL RESULTS AND NEED FOR FINANCING
  • We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.
  • We have incurred substantial losses, expect to continue to incur substantial losses for the foreseeable future and may never generate significant revenue or achieve or maintain profitability.
  • We will require substantial additional capital, which may be difficult to obtain, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our drug development program or commercialization efforts, and our ability to continue operations could be adversely affected.
  • If the estimates we make and the assumptions on which we rely in preparing our financial statements prove inaccurate, our actual results may vary significantly.
  • RISKS RELATING TO THE DEVELOPMENT AND COMMERCIALIZATION OF OUR DRUG CANDIDATES
  • We depend heavily on the success of emavusertib. Emavusertib is still in early clinical development. Clinical trials of emavusertib may not be successful. If we are unable to commercialize emavusertib or experience significant delays in doing so, our business will be materially harmed.
  • The therapeutic efficacy of emavusertib is unproven in humans, and we may not be able to successfully develop and commercialize emavusertib.
  • If we experience delays in the enrollment of patients in our clinical trials of emavusertib, our receipt of necessary regulatory approvals could be delayed or prevented.
  • Results of preclinical studies and early clinical trials may not be predictive of results of future late stage clinical trials, and interim, “top-line,” initial, and preliminary data from our clinical trials may change as more patient data become available or as additional analyses are conducted and audit and verification procedures could result in material changes to the final data.
  • We have never obtained marketing approval for a drug candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for emavusertib or any future drug candidates that we, or any future collaborators, may develop.
  • Even if any drug candidates that we, or any collaborators, may develop receive marketing approval, we or others may later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, which could compromise our ability, or that of any collaborators, to market the drug.
The other 51 risks
  • Even if emavusertib receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable.
  • We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • We currently have no sales, marketing, or distribution experience and, as such, we must build infrastructure related to product sales, marketing and distribution or make arrangements with third parties to perform these services, and any such third parties may not successfully market or sell any drugs we develop.
  • We face substantial competition, and our competitors may discover, develop or commercialize drugs before or more successfully than we do.
  • Even if we, or any collaborators, are able to commercialize any drug candidate that we, or they, develop, the drug may become subject to unfavorable pricing regulations, third party payor reimbursement practices or healthcare reform initiatives, any of which could harm our business.
  • Product liability lawsuits against us or our collaborators could divert our resources, cause us to incur substantial liabilities and limit commercialization of any drugs that we may develop.
  • RISKS RELATING TO OUR DEPENDENCE ON THIRD PARTIES
  • We may not be successful in establishing additional strategic collaborations, which could adversely affect our ability to develop and commercialize emavusertib, which we have strategically determined to pursue with a collaborator.
  • We rely heavily on third parties to conduct clinical trials of emavusertib, and if such third parties perform inadequately, including failing to meet deadlines for the completion of such trials, research or testing, then we may not be able to successfully develop and commercialize emavusertib and grow our business.
  • We depend on third parties to produce emavusertib, and if these third parties do not successfully formulate or manufacture the drug candidate, our business could be harmed.
  • Because we rely on a limited number of suppliers for the raw materials used in emavusertib, any delay, shortage or interruption in the supply of such raw materials or contamination in our manufacturing process could lead to delays in the manufacture and supply of emavusertib.
  • We depend on third parties for the research and, as applicable, development and commercialization of our drug candidates. If one or more of our collaborators fails or delays in developing or, as applicable, commercializing our drug candidates based upon our technologies, our business prospects and operating results could suffer and our stock price could decline.
  • We depend upon companion drugs in the conduct of our clinical trials. If companion drug is not available, our development of emavusertib could experience significant delays which could have a material adverse effect on our business.
  • RISKS RELATING TO EMPLOYEE MATTERS AND MANAGING GROWTH
  • If we are not able to attract and retain key management and scientific personnel and advisors, we may not successfully develop emavusertib or achieve our other business objectives.
  • We may in the future seek to acquire complementary businesses and technologies or otherwise seek to expand our operations and grow our business, which may divert management resources and adversely affect our financial condition and operating results.
  • RISKS RELATING TO OUR INTELLECTUAL PROPERTY
  • We may not be able to obtain and maintain patent protection for our technologies and drugs, our licensors may not be able to obtain and maintain patent protection for the technology or drugs that we license from them, and the patent protection we or they do obtain may not be sufficient to stop our competitors from using similar technology.
  • We may become involved in expensive and unpredictable patent litigation or other contentious intellectual property proceedings, which could result in liability for damages or require us to cease our development and commercialization efforts.
  • We face risks relating to the enforcement of our intellectual property rights in China and India that could adversely affect our business.
  • If we are unable to keep our trade secrets confidential, our technology and proprietary information may be used by competitors.
  • We have agreements under which we license rights to technology from third parties, and we could lose license rights to intellectual property that are important to our business under certain circumstances.
  • We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
  • RISKS RELATING TO REGULATORY APPROVAL AND MARKETING OF OUR DRUG CANDIDATES AND OTHER LEGAL COMPLIANCE MATTERS
  • Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of emavusertib. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize emavusertib.
  • Failure to obtain marketing approval in foreign jurisdictions would prevent emavusertib from being marketed abroad. Any approval we may be granted for emavusertib in the U.S. would not assure approval of emavusertib in foreign jurisdictions and if emavusertib is approved for marketing in a foreign jurisdiction, it will be subject to risk associated with foreign operations.
  • We, or any future collaborators, may not be able to obtain orphan drug designation or orphan drug exclusivity for emavusertib and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving competing products.
  • If we, or our collaborators, obtain marketing approval for emavusertib, it will be subject to ongoing regulation and could be subject to restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements, when and if emavusertib is approved.
  • We may seek approval from the FDA or comparable foreign regulatory authorities to use accelerated development pathways for our drug product candidates. If we are not able to use such pathways, we may be required to conduct additional clinical trials beyond those that are contemplated, which would increase the expense of obtaining, and delay the receipt of, necessary marketing approvals, if we receive them at all. In addition, even if an accelerated approval pathway is available to us, it may not lead to expedited approval of our drug product candidates, or approval at all.
  • We may seek certain designations for emavusertib, including Breakthrough Therapy and Fast Track designations, in the U.S., and PRIME Designation in the EU, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.
  • If we are required by the FDA to obtain clearance or approval of a companion diagnostic in connection with approval of a candidate therapeutic product, and we do not obtain or there are delays in obtaining FDA clearance or approval of a diagnostic device, we will not be able to commercialize the drug candidate and our ability to generate revenue will be materially impaired.
  • Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development program and develop and secure approval of our product candidates in a timely manner, which would negatively impact our business.
  • If the FDA, EMA or other comparable foreign regulatory authorities approve generic versions of any of our small molecule investigational products that receive marketing approval, or such authorities do not grant our products appropriate periods of exclusivity before approving generic versions of those products, the sales of our products, if approved, could be adversely affected.
  • Current and future legislation may increase the difficulty and cost for us and any future collaborators to obtain reimbursement for any drug candidate that does receive marketing approval and our ability to generate revenue will be materially impaired.
  • The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed.
  • We may be subject to certain healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, fines, disgorgement, exclusion from participation in government healthcare programs, curtailment or restricting of our operations, and diminished profits and future earnings.
  • Analogous State and Foreign Laws.
  • We are subject to stringent privacy laws, information security laws, regulations, policies, and contractual obligations and failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.
  • We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business.
  • We are subject to governmental export and import controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws.
  • Changes in and uncertainty surrounding U.S. trade policy and international trade policies, particularly with respect to China, could have a material adverse impact on our business, financial condition and results of operations.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.
  • Our employees may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.
  • Our internal computer systems, or those of any collaborators or contractors or consultants, may fail or suffer security breaches or other cyber incidents, which could result in a material disruption of our product development program.
  • RISKS RELATING TO OUR COMMON STOCK
  • If we fail to maintain compliance with Nasdaq Capital Market’s listing requirements, our common stock could be delisted from trading, which would decrease the liquidity of our common stock and our ability to raise additional capital.
  • Our stock price has and is likely to continue to fluctuate significantly and the market price of our common stock could drop below the price paid by our investors.
  • Fluctuations in our quarterly and annual operating results could adversely affect the price of our common stock which could result in substantial losses for purchasers of our common stock.
  • We and our collaborators may not achieve projected research, development, commercialization and marketing goals in the time frames that we or they announce, which could have an adverse impact on our business and could cause our stock price to decline.
  • Future sales of shares of our common stock, including by us, employees and large stockholders, including pursuant to our 2024 Sales Agreement with Cantor and JonesTrading could result in dilution to our stockholders and negatively affect our stock price.
  • We do not intend to pay dividends on our common stock, and any return to investors will come, if at all, only from potential increases in the price of our common stock.
  • We have anti-takeover defenses that could delay or prevent an acquisition that our stockholders may consider favorable, or prevent attempts by our stockholders to replace or remove current management, which could result in a decline in the price of our common stock.
  • GENERAL RISK FACTORS
  • If we are not able to maintain effective internal controls under Section 404 of the Sarbanes-Oxley Act, our business and stock price could be adversely affected.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
  • We are subject to risks associated with public health crises and epidemics/pandemics.

Legal proceedings

We are currently not a party to any material legal proceedings.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83